---
title: "Atara Biotherapeutics, Inc. (ATRA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ATRA.US.md"
symbol: "ATRA.US"
name: "Atara Biotherapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T14:08:19.569Z"
locales:
  - [en](https://longbridge.com/en/quote/ATRA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ATRA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ATRA.US.md)
---

# Atara Biotherapeutics, Inc. (ATRA.US)

## Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.atarabio.com](https://www.atarabio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.60)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 279 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -88.41% |  |
| Net Profit YoY | 39.47% |  |
| P/B Ratio | -2.09 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 77887288.80 |  |
| Revenue | 23139000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 20.49% | A |
| Profit Margin | -40.91% | E |
| Gross Margin | 75.97% | A |
| Revenue YoY | -88.41% | E |
| Net Profit YoY | 39.47% | B |
| Total Assets YoY | -67.77% | E |
| Net Assets YoY | 32.25% | A |
| Cash Flow Margin | 273.32% | A |
| OCF YoY | -88.41% | E |
| Turnover | 0.56 | C |
| Gearing Ratio | 286.59% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Atara Biotherapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-88.41%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "39.47%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-2.09",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "77887288.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "23139000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "20.49%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-40.91%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "75.97%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-88.41%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "39.47%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-67.77%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "32.25%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "273.32%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-88.41%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.56",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "286.59%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.23 | 427/386 | 14.98 | 4.32 | 1.32 |
| PB | -2.09 | 494/386 | - | - | - |
| PS (TTM) | 3.37 | 76/386 | 0.60 | 0.37 | 0.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Hold | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 9.42 |
| Highest Target | 18.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ATRA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ATRA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ATRA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ATRA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**